These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 21643519)

  • 21. The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.
    Vasilakos JP; Tomai MA
    Expert Rev Vaccines; 2013 Jul; 12(7):809-19. PubMed ID: 23885825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trial watch: Toll-like receptor ligands in cancer therapy.
    Le Naour J; Kroemer G
    Oncoimmunology; 2023; 12(1):2180237. PubMed ID: 36875550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma.
    Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J
    Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Toll or toll-free adjuvant path toward the optimal vaccine development.
    Ishii KJ; Akira S
    J Clin Immunol; 2007 Jul; 27(4):363-71. PubMed ID: 17370119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of Toll-like receptor signaling in innate immunity by natural products.
    Chen L; Yu J
    Int Immunopharmacol; 2016 Aug; 37():65-70. PubMed ID: 26899347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Application of toll-like receptor agonists as an adjuvant component to malaria blood-stage vaccine].
    Xie CB; Qian F; Xu HJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2011 Oct; 29(5):389-93. PubMed ID: 24830205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TLR Agonists as Adjuvants for Cancer Vaccines.
    Li JK; Balic JJ; Yu L; Jenkins B
    Adv Exp Med Biol; 2017; 1024():195-212. PubMed ID: 28921471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics.
    Jarnicki AG; Conroy H; Brereton C; Donnelly G; Toomey D; Walsh K; Sweeney C; Leavy O; Fletcher J; Lavelle EC; Dunne P; Mills KH
    J Immunol; 2008 Mar; 180(6):3797-806. PubMed ID: 18322186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent clinical trends in Toll-like receptor targeting therapeutics.
    Anwar MA; Shah M; Kim J; Choi S
    Med Res Rev; 2019 May; 39(3):1053-1090. PubMed ID: 30450666
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection.
    Gill N; Davies EJ; Ashkar AA
    Am J Reprod Immunol; 2008 Jan; 59(1):35-43. PubMed ID: 18154594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Therapeutic potential of toll-like receptors in treatment of gynecological cancers.
    Moradi-Marjaneh R; Hassanian SM; Hasanzadeh M; Rezayi M; Maftouh M; Mehramiz M; Ferns GA; Khazaei M; Avan A
    IUBMB Life; 2019 May; 71(5):549-564. PubMed ID: 30729633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of innate responses induced by in ovo administration of encapsulated and free forms of ligands of Toll-like receptor 4 and 21 in chicken embryos.
    Bavananthasivam J; Alkie TN; Matsuyama-Kato A; Hodgins DC; Sharif S
    Res Vet Sci; 2019 Aug; 125():405-415. PubMed ID: 29126629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic targeting of the innate immune system in domestic animals.
    Coffey TJ; Werling D
    Cell Tissue Res; 2011 Jan; 343(1):251-61. PubMed ID: 20953632
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential use of Toll-like receptor (TLR) agonists and antagonists as prophylactic and/or therapeutic agents.
    Makkouk A; Abdelnoor AM
    Immunopharmacol Immunotoxicol; 2009; 31(3):331-8. PubMed ID: 19555209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drugs targeting Toll-like receptors.
    Krishnan J; Lee G; Choi S
    Arch Pharm Res; 2009 Nov; 32(11):1485-502. PubMed ID: 20091261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toll-like receptor agonists: a patent review (2011 - 2013).
    Hussein WM; Liu TY; Skwarczynski M; Toth I
    Expert Opin Ther Pat; 2014 Apr; 24(4):453-70. PubMed ID: 24456079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist.
    Vicari AP; Schmalbach T; Lekstrom-Himes J; Morris ML; Al-Adhami MJ; Laframboise C; Leese P; Krieg AM; Efler SM; Davis HL
    Antivir Ther; 2007; 12(5):741-51. PubMed ID: 17713157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Toll-like receptors: cost or benefit for cancer?
    Matijevic T; Pavelic J
    Curr Pharm Des; 2010; 16(9):1081-90. PubMed ID: 20030618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Toll-like receptors: recognition receptors of the innate immune system and target structures for therapeutical intervention].
    Kabelitz D
    Med Monatsschr Pharm; 2012 Jul; 35(7):238-44. PubMed ID: 22852274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants.
    Kumar S; Sunagar R; Gosselin E
    Front Immunol; 2019; 10():1144. PubMed ID: 31191528
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.